Florida State University News
Richard McCullough selected next president of Florida State University
May 24, 2021 | 4:36 pm | SHARE:
The Florida State University Board of Trustees has unanimously selected Richard McCullough, vice provost for research at Harvard University, to serve as the university’s 16th president.
McCullough will succeed John Thrasher, who will retire later this summer after serving as president since 2014.
The appointment is subject to approval by the Florida Board of Governors, which meets June 23.
“It is an honor to have the opportunity to lead Florida State University as its next president,” McCullough said. “Public universities are amazing engines of social change and mobility, and FSU is leading the way in that effort. The foundation is set for FSU to take its next jump up, and I’m excited to be a part of the team that will take it to the next level.”
Housing and Development Newsletter
According to ISCS, DenBaars “has made seminal contributions to the science of nitride materials, and is recognized as an international authority on the growth and structure of nitride semiconductors by metal-organic chemical vapor deposition (MOCVD). He has performed pioneering work on polar, non-polar and semi-polar Gallium nitride (GaN) materials and devices.”
A professor of materials who holds the university’s Mitsubishi Chemical Chair, DenBaars joined the campus in 1991. In 1997 he and fellow GaN expert Umesh Mishra co-founded Nitres, Inc., one of the first GaN startups in the United States. Nitres was acquired by Cree, Inc. in May 2000.
Internationally Renowned Clinician Scientist Camillo Ricordi Head of Diabetes Research Institute Joins Creative Medical Technology Holdings
Immunologist Surgeon who Invented Islet Transplantation to Assist Company in Advancing ImmCelz® Platform
News provided by
Share this article
Share this article
PHOENIX, May 20, 2021 /PRNewswire/ Creative Medical Technology Holdings announced today recruitment of Dr. Camillo Ricordi to the Company s Scientific Advisory Board. Dr. Ricordi will collaborate with Company Advisors such as Drs Timothy Henry, Santosh Kesari, Ceagan Du, and Boris Reznik in accelerating advancement of its ImmCelz® Regenerative Immunotherapy platform. Currently the Company is engaged with the FDA regarding clearance of its IND # 27375 covering the use of ImmCelz® to treat stroke.
Luminaries | The UCSB Current ucsb.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ucsb.edu Daily Mail and Mail on Sunday newspapers.
2020-2021 Year in Review nyu.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nyu.edu Daily Mail and Mail on Sunday newspapers.